MOMA Therapeutics is a clinical-stage, next-generation precision medicine company dedicated to targeting highly dynamic proteins that underlie human disease via a small molecule approach, utilizing its proprietary KNOMATIC platform. The platform was designed to exploit key vulnerabilities inherent to all dynamic proteins, namely their dependence on well-coordinated, stepwise changes in protein conformation. By focusing on genetically validated targets with high translation potential MOMA is rapidly advancing its pipeline toward responses in the clinic. In January 2024, MOMA announced a five-year discovery collaboration with Roche focused on critical cancer dependencies. We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in need. We’ve removed the bureaucracy and believe having a teammate’s back is critical to our success. You see, MOMA isn’t your typical biotech company. We are drug discovery professionals, industry specialists and scientific experts. More importantly, we’re collectively unstoppable.
MOMA Therapeutics的外部链接
20 Acorn Park Drive
6th Floor
US，Massachusetts，Cambridge ，02140
As we begin to say goodbye to the summer months in Boston, we’re reflecting on the major accomplishments we made and special moments MOMAtes shared, from well-earned ice cream breaks to our wellness challenge. Our team’s dedication and passion have driven us forward and we’re excited to carry this momentum into the rest of the year!
As a clinical-stage company, MOMA has a significant responsibility not only to pursue the power of highly dynamic proteins that underlie human disease, but to do so rapidly and skillfully for patients in need. We’re advancing two wholly-owned, potentially best-in-class, #oncology assets enabled by our proprietary KNOMATIC Platform. Hear from the team on what this next stage means to us, and how we’re committed to adapting and evolving in rhythm with company growth. Learn more: https://lnkd.in/efssQfgT
MOMA Chief People and Experience Officer,?Adam Thomas (he/him) will be at the Cambridge Healthtech Institute #CHIBioprocessingSummit?today, taking part in two panels during their "Talent in Biopharma" workshop. We're excited for Adam to offer his expert perspective?alongside other industry leaders on their best people practices and growth strategies. Check it out and register:?https://lnkd.in/eqYsS33
Today marks a significant milestone for MOMA. We have dosed the first patient in the Phase 1 clinical trial for MOMA-313, a novel, highly potent and selective oral polymerase theta helicase inhibitor. MOMA-313 is being developed for subgroups of #prostatecancer, #pancreaticcancer and #breastcancer. To add to this exciting news, we are thrilled to share the selection of a development candidate for our second lead program, MOMA-341, an oral, potent and selective covalent Werner helicase inhibitor for the treatment of cancers with microsatellite instability. The MOMA team has worked hard to bring these two potential best-in-class molecules to the clinic through our proprietary KNOMATIC platform. Learn more about our MOMA-313, MOMA-341 and our KNOMATIC platform from MOMA CEO, Asit Parikh, M.D., Ph.D., below and read the release: https://lnkd.in/eVd3qR46
Our proprietary platform has been intentionally?designed?with optimized components?for?the sole purpose of drugging highly dynamic proteins and is built with unprecedented scale. With the power of #machinelearning and #AI, we can predict hit-finding outcomes with greater accuracy and enable a continuous learning loop that builds upon and expands our knowledge base, increasing?sophistication and efficiency in our drug discovery endeavors. Learn more about our platform below and at?momatx.com.
MOMA's mission is all about harnessing the power of?highly dynamic proteins?- but what are they??Highly dynamic proteins?- often referred to as "molecular machines” - drive many cellular processes that underlie human disease. They are historically hard to drug because of their ability to?shapeshift. We're focusing on the potential of this target class with two wholly-owned?lead oncology assets, alongside a strong pipeline of high-value pre-clinical candidates so we can bring?a new generation of?precision therapeutics to patients in need. Learn more about highly dynamic proteins below and at?momatx.com.
Stepping up to the plate this summer are four of our incredible new interns! Derya Balata, Shannon Lamond, Wilhen Alberto Hui Mei and Daria Mandel recently joined the MOMA team at an exciting time to learn more about our pursuit of #precisionmedicine and expand their knowledge into lab operations, computational chemistry, computational biology, HR and communications with our unstoppable team. Learn more about each of them in their MOMAte cards below.
We were honored to have Jeff Sigel, the newly published author of "The Middle Matters," join us for our recent Development Capability Session. During these sessions, Jeff shared his perspective on owning your career development through continuous self-improvement, proactive leadership, and identifying different ways to work, manage, and increase visibility. Current and future people managers also learned more about building up a team, active leadership, defining purpose and how to provide feedback to encourage growth. At MOMA, we’re deeply committed to enabling and supporting our MOMAtes on their career journey so they #LovetheJourney. Development activities like these help encourage growth and equip every MOMAte with the tools to succeed. A huge thank you to Jeff Sigel for sharing his insights and wisdom with us!
Sending a big congratulations to MOMA founder, Dorothee Kern, PhD, on her exciting new role at Scripps Research as an Investigator for the Howard Hughes Medical Institute! We're thrilled to see her make a continuous impact on the field and for bringing her expert insights on protein dynamics at the heart of biology and rational drug design to the Scripps team. Read more:?https://lnkd.in/e8z6vDYA
We're excited to extend a warm MOMA welcome to Marc Ballas, MD, and Adam Thomas (he/him). Marc joins as our Head of Clinical Development, after a successful assignment at Novocure. He will oversee MOMA's clinical function, focusing on developing our precision oncology assets as they progress into the clinic. Adam has joined as our Chief People & Experience Officer and brings more than 20 years of experience in human resources and business operations, with a focus on talent development, team building and organizational effectiveness. We look forward to utilizing their experience as we make the transition from research into development and work to deliver breakthrough #precisionmedicine therapies. It is an exciting moment for MOMA! Read more: https://lnkd.in/ei4z4Xu4